When should hydrochlorothiazide be held (e.g., hypotension, volume depletion, hyponatremia, hypokalemia, hyperuricemia, eGFR <30 mL/min/1.73 m², acute rise in creatinine, before major surgery or contrast‑enhanced imaging)?

When to Hold Hydrochlorothiazide

Hydrochlorothiazide should be held when eGFR falls below 30 mL/min/1.73 m², when systolic blood pressure drops below 90 mmHg, when serum sodium falls below 125 mmol/L, when serum potassium drops below 3.0 mmol/L, or during acute illness with vomiting, diarrhea, or decreased oral intake. 1, 2, 3

Critical Thresholds for Holding HCTZ

Renal Function

• Hold HCTZ when eGFR falls below 30 mL/min/1.73 m² or serum creatinine exceeds 221 μmol/L (>2.5 mg/dL), as thiazides become ineffective and may worsen renal function at this threshold. 1, 2
• Thiazides lose their diuretic efficacy when GFR drops below this level and should be replaced with loop diuretics if ongoing diuresis is needed 1

Hypotension

• Hold HCTZ when systolic blood pressure falls below 90 mmHg, whether symptomatic or asymptomatic, as diuretic-induced hypovolemia will worsen hypotension. 1
• Symptomatic hypotension causing dizziness or lightheadedness mandates immediate discontinuation if no signs of congestion are present 1

Hyponatremia

• Stop HCTZ immediately when serum sodium falls below 125 mmol/L, as thiazide-induced hyponatremia can progress to life-threatening hyponatremic encephalopathy. 2, 3
• Elderly women face substantially elevated risk of severe hyponatremia with HCTZ and require closer monitoring 2
• Switch to a loop diuretic if diuresis is still needed, as loop diuretics are less likely to cause severe hyponatremia 1

Hypokalemia

• Hold HCTZ when serum potassium drops below 3.0 mmol/L, as this level significantly increases the risk of life-threatening cardiac arrhythmias, particularly in patients with heart disease or on digoxin. 1, 2
• For patients with cardiac disease or on digoxin, consider holding HCTZ even at potassium levels of 3.0-3.5 mmol/L 1
• The combination of hypokalemia and hypomagnesemia (which commonly coexist with thiazide use) dramatically increases arrhythmia risk 2, 3

Volume Depletion

• Hold HCTZ during acute illness with vomiting, diarrhea, or decreased oral intake, as these conditions cause additional volume and electrolyte losses that compound thiazide effects. 2, 3
• Signs of hypovolemia/dehydration (orthostatic hypotension, tachycardia, decreased skin turgor, concentrated urine) mandate immediate discontinuation 1

Perioperative Management

Before Major Surgery

• Continue HCTZ if blood pressure is stable and well-controlled, but hold it on the morning of surgery if systolic blood pressure is below 140 mmHg or if there are signs of volume depletion. 1
• The 2016 joint guidelines from the Association of Anaesthetists and British Hypertension Society recommend continuing chronic thiazide therapy in stable patients rather than routine discontinuation 1
• Verify electrolytes are within acceptable ranges (K+ 4.0-5.0 mEq/L, Na+ >135 mmol/L) before proceeding with elective surgery 1

Contrast-Enhanced Imaging

• Hold HCTZ 24-48 hours before contrast-enhanced imaging in patients with eGFR 30-60 mL/min/1.73 m² or in those at high risk for contrast-induced nephropathy. 1
• Ensure adequate hydration before contrast administration, as volume depletion from HCTZ increases the risk of acute kidney injury 1

Special Populations Requiring Caution

Elderly Patients

• Elderly patients are more susceptible to orthostatic hypotension, renal function deterioration, and electrolyte abnormalities with HCTZ, requiring more frequent monitoring and lower thresholds for holding the medication. 1
• Monitor supine and standing blood pressure regularly, as orthostatic hypotension is common 1

Heart Failure Patients

• In heart failure patients, hold HCTZ only if there is symptomatic hypotension without signs of congestion, as persistent volume overload limits the efficacy and safety of other heart failure medications. 1
• Excessive concern about hypotension and azotemia can lead to underutilization of diuretics and refractory edema 1
• Continue diuresis until fluid retention is eliminated, even if this results in mild to moderate decreases in blood pressure or renal function, as long as the patient remains asymptomatic 1

Monitoring Requirements

Electrolyte Monitoring

• Check serum electrolytes within 2-4 weeks of HCTZ initiation or dose escalation, as the greatest electrolyte shifts occur within the first 3 days of administration. 2, 3
• Monitor potassium, sodium, magnesium, and creatinine at 1-2 weeks after initiation, then at 3 months, and every 3-6 months thereafter 1, 2

Clinical Monitoring

• Monitor for unexplained neurological symptoms (nausea, vomiting, headache, confusion, lethargy) that may indicate hyponatremic encephalopathy requiring immediate electrolyte measurement. 2
• Assess volume status using daily weights and physical examination 1

Common Pitfalls to Avoid

• Never continue HCTZ in patients with eGFR <30 mL/min/1.73 m² expecting a diuretic effect, as it is ineffective at this level of renal function. 1, 2
• Do not ignore mild hyponatremia (130-135 mmol/L) in elderly patients, as it can rapidly progress to severe, life-threatening hyponatremia. 2, 4
• Avoid combining HCTZ with NSAIDs, as this combination causes diuretic resistance, worsens renal function, and increases hyperkalemia risk when combined with ACE inhibitors or ARBs. 1, 2
• Do not restart HCTZ after holding for hypokalemia without first correcting magnesium levels, as hypomagnesemia makes hypokalemia resistant to correction. 2, 3